InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First Neuro-Spinal
Scaffold™ Implantation
InVivo Therapeutics Holdings Corp. (NVIV) today announced the publication of a case report in the journal
Neurosurgery detailing the first clinical Neuro-Spinal Scaffold implantation. Neurosurgery is the official
journal of the Congress of Neurological Surgeons. Nicholas Theodore, M.D., is the lead author of the article, titled, “First Human
Implantation of a Bioresorbable Polymer Scaffold for Acute Traumatic Spinal Cord Injury: A Clinical Pilot Study for Safety and
Feasibility.” The article describes the clinical presentation, surgical procedure, and postoperative improvement of the first
patient in the INSPIRE study through the patient’s 6-month follow-up.
Dr. Theodore said, “I am gratified that the case report detailing the safety and feasibility of the implantation of the
Neuro-Spinal Scaffold was published in a distinguished journal. The patient’s improvement to date has been notable and
provides the basis for my continued enthusiasm for the INSPIRE study.”
“We are very pleased to have the first clinical Neuro-Spinal Scaffold case report published in a leading, peer-reviewed
neurosurgical journal,” Mark Perrin, InVivo’s CEO and Chairman, said. “We have been steadily increasing awareness in the
neurosurgical community and look forward to additional publications on the INSPIRE study.”
The publication is now available electronically through Neurosurgery prior to print publication at:
http://journals.lww.com/neurosurgery/Abstract/publishahead/First_Human_Implantation_of_a_Bioresorbable.97328.aspx
About The INSPIRE Study
The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and
Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and
probable benefit of the Neuro-Spinal Scaffold for the treatment of complete T2-T12/L1 spinal cord injury in support of
a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the
decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity
formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated
in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord
injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements can be identified by words such as "believe,"
"anticipate," "intend," "estimate," "will," "may," "should," "expect," “designed to,” “potentially,” and similar expressions, and
include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and future publications. Any forward-looking
statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that
could cause actual future results to differ materially from current expectations include, but are not limited to, risks and
uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board process; the impact of achieving the OPC on the FDA approval
process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on
its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of
spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct
research and development, clinical studies and future product commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and
described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings
with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these
forward-looking statements.
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005162/en/